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Mutations in NOTCH 3 are the cause of cerebral autosomal dominant arteriopathy with subcortical in-
farcts and leukoencephalopathy (CADASIL), a neurological disorder characterized by stroke, and vascular
cognitive impairment and dementia. Loss of vascular smooth muscle cells (VSMC) and accumulation of
granular osmiophilic material (GOM) deposits are hallmarks of CADASIL. There are no therapies for
CADASIL and experimental endpoints to examine the preclinical efﬁcacy of potential drugs are lacking.
This study aims to use a mouse carrying the C455R mutation in Notch 3 to identify biomarkers associated
with CADASIL.
Mass spectrometry and antibody arrays were used to explore the aorta and blood proteomes of
CADASIL mice, ELISA assays were utilized for biomarker validation, a ligand-dependent assay was applied
to examine the relationship between Notch signaling and biomarker expression, and retinal histology
was performed for quantiﬁcation of VSMC loss in arteries. Two-hundred day-old mice with the C455R
CADASIL mutation in Notch 3 mice display robust VSMC loss in retinal arteries and had increased plasma
levels of collagen18α1/endostatin (col18α1) and high-temperature requirement A serine peptidase 1
(HTRA1) and reduced levels of Notch 3 extracellular domain (N3ECD), compared to control wild type
mice.
Measurements of plasma endostatin, HTRA1 and N3ECD, along with VSMC quantiﬁcation in retinal
arteries, may serve as surrogate endpoints for assessing efﬁcacy in preclinical therapeutic studies of
CADASIL using mice.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Ischemic cerebral small-vessel disease (SVD) is a prevalent
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asquez).impairment and dementia (Snyder et al., 2015). Multiple clinical
studies show strong an association among SVD, aging, and cardi-
ovascular risk factors (Kalaria, 2012; Thompson and Hakim, 2009;
Vermeer et al., 2007). Little is known about the cellular and mo-
lecular mechanisms underlying the development of SVD and
therapies are lacking. Mendelian conditions resembling key as-
pects of SVD, in the absence of cardiovascular risk factors, have
been described in adult patients (Gould et al., 2006; Hara et al.,
2009; Joutel and Faraci, 2014). The study of these inherited SVDs
may reveal key pathophysiological mechanisms, uncover bio-
markers with diagnostic or prognostic potential, and deﬁne mo-
lecular targets for rational therapeutics. One such SVD is cerebral
autosomal dominant arteriopathy with subcortical infarcts and
leukoencephalopathy, (CADASIL), the most common form of in-
herited SVD (Chabriat et al., 2009).e under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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hood, have recurrent ischemic strokes in the third and fourth
decade of life, and experience progressive cognitive impairment
(Dichgans et al., 1998). CADASIL is caused by mutations in the
NOTCH 3 gene, which encodes for one of four Notch receptor
paralogues in mammals (Joutel et al., 1996). Most CADASIL muta-
tions in Notch 3 affect cysteine residues located within the epi-
dermal growth factor-like repeats in the extracellular domain
(Brass et al., 2009; Dichgans et al., 2000; Joutel et al., 1997; Louvi
et al., 2006). Postmortem studies of tissue from CADASIL patients
reveal a non-amyloid, non-atherosclerotic, arteriopathy. The
characteristics of this arteriopathy include VSMC death and the
accumulation of deposits, detected by electron microscopy, known
as granular osmiophilic material (GOM) (Baudrimont et al., 1993;
Ruchoux et al., 1995; Ruchoux and Maurage, 1997; Tikka et al.,
2009). GOM deposits are speciﬁc to CADASIL and their identiﬁca-
tion in skin biopsies or brain autopsies is diagnostic (Tikka et al.,
2009). Biochemical studies of vessels of postmortem CADASIL
cases and mouse models identiﬁed collagen 18 alpha 1(Col18α1)/
endostatin, clusterin (Arboleda-Velasquez et al., 2011), Notch
3 ectodomain (N3ECD), and tissue inhibitor of metalloproteinases
3 (TIMP3) as GOM components (Ishiko et al., 2006; Monet-Le-
pretre et al., 2013).
For the current work, we studied published CADASIL mouse
models carrying either the C455R or R1031C mutations in Notch 3.
The C455R CADASIL mutation was described in a Colombian family
in whom stroke occurs earlier and MRI abnormalities are more
extensive than in patients carrying the R1031C, also described in a
Colombian pedigree (Arboleda-Velasquez et al., 2002). Previous
work showed that the C455R (located in the ligand-binding do-
main of the Notch 3 receptor) and the R1031C (located outside thisFig. 1. Proteomic screen in CADASIL mice. Dot blots represent levels of speciﬁc proteins, i
or 200 days of age (N3KO; C455Rþ/; SM22-Cre) and two control (N3KO; WT76þ/
entially expressed, as established by a variance analysis.region) mutations deﬁne different hypomorphic activity states of
the Notch 3 receptor and that mice carrying these mutations de-
velop GOM and other age-dependent phenotypes that resemble
the human condition (Arboleda-Velasquez et al., 2011).
The availability of multiple CADASIL animal models, including
those used in this work, may allow for preclinical testing of ex-
perimental drugs (Arboleda-Velasquez et al., 2011; Joutel and
Faraci, 2014). Such studies would be greatly facilitated by the
identiﬁcation of speciﬁc markers of disease progression that are
measurable, sensitive, and robust. Here, we sought to identify
blood biomarkers associated with CADASIL in a mouse model
carrying non-synonymous mutations in Notch 3. We utilized blood
plasma, from knock-in mice models carrying Notch 3 mutations
identical to those found in Colombian families (Arboleda-Ve-
lasquez et al., 2008, 2011) for biomarker discovery and validation.2. Results
2.1. Screening of CADASIL biomarkers in mouse plasma
Previous analyses of mice and humans carrying CADASIL mu-
tations in Notch 3 identiﬁed col18α1/endostatin, a potent and
pleiotropic anti-angiogenic factor, as a protein accumulating in
CADASIL vessels and a GOM component (Arboleda-Velasquez
et al., 2011; O’Reilly et al., 1997). We used an antibody array cap-
able of detecting 53 angiogenesis-related proteins to determine
whether endostatin, and/or other angiogenesis-related proteins,
could be detected in plasma samples from our transgenic mice. We
compared the plasma of knock-in mice expressing the human WT
Notch 3 protein (N3KO; WT76þ/; SM22-Cre) to that of micen technical duplicate, found in plasma from two male CADASIL mice collected at 100
; SM22-Cre). IGFBP-1, SDF-1, and collagen18α1/endostatin were found to be differ-
Fig. 2. Proteomic screen in N3KO mice. Dot blots show levels of speciﬁc proteins found in plasma from two male notch 3 knockout (N3KO) mice (200 d) or two rescued/
control (N3KO; WT76þ/; SM22-Cre) in which a wild type human Notch 3 is expressed in VSMC. Col18α1/endostatin was found to be differentially expressed, as estab-
lished by a variance analysis.
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; SM22-Cre) at 100 and 200 days old, all in a mouse endogenous
notch 3 knockout background (N3KO) (Fig. 1 and Supplemental
Fig. 1A). Furthermore, to examine whether any angiogenic-related
protein candidates were regulated by Notch 3 function, we also
compared their expression in plasma from 200-day old mice
lacking notch 3, N3KO, and N3KO mice in which Notch 3 expres-
sion was restored in vessels using a conditional transgenic ap-
proach, N3KO; WT76þ/; SM22-Cre mice (Fig. 2 and Supple-
mental Fig. 1A).
We identiﬁed insulin-like growth factor-binding protein-1
(IGFBP-1), stromal cell-derived factor-1 (SDF-1), and col18α1/en-
dostatin as potential biomarkers based on a variance analysis (see
Methods). IGFBP-1 was increased in both 100- and 200-day old
N3KO; C455Rþ/; SM22-Cre mice (Fig. 1 and Supplemental
Fig. 1A), with a fold change of 2.029 and 4.562, respectively). SDF-1
was more abundant in 100-day old N3KO; C455Rþ/SM22-Cre
mice (1.752-fold-hange) and less abundant in the 200-day old
N3KO; C455Rþ/; SM22-Cre mice (0.344-fold change, Fig. 1 andFig. 3. Endostatin is misregulated in CADASIL. (A) ELISA detection of endostatin in pla
C455Rþ/; SM22-Cre), or control (N3KO; WT76þ/; SM22-Cre) showing that there
Number of biological replicates is indicated in parenthesis. (B) Primary cultures of MEFs f
were placed in monocultures or cocultures with cells expressing DLL1 (ROSA26DLL1þ /
pression, whereas cocultures with DLL1 signiﬁcantly increased col18α1 mRNA express
cultures compared to N3KO; C455Rþ/þ cocultures. Asterisks (*) indicate P-value o0.0Supplemental Fig. 1A). Col18α1/endostatin, was signiﬁcantly less
abundant (0.800 fold change) in the 100-day-old N3KO; C455Rþ/
; SM22-Cre mice, but, remained unchanged (1.025-fold change)
in the 200-day old mice (Fig. 1 and Supplemental Fig. 1A). Because
protein-protein interactions within complex samples have been
reported when using antibody arrays (Kodadek, 2001)., ELISA was
utilized to validate the results. Analysis in 200-day old N3KO;
C455Rþ/; SM22-Cre mouse plasma using ELISA showed a sig-
niﬁcant increase in plasma circulating col18α1/endostatin (Fig. 3A,
1.76-fold change, Po0.01).
IGFBP-1 and SDF-1 levels were not changed in the plasma of
mice from functional rescue comparison (N3KO vs. N3KO;
WT76þ/; SM22-Cre), whereas col18α1/endostatin was more
abundant in the N3KO; WT76þ/; SM22-Cre mouse when com-
pared to the N3KO mouse, suggesting that col18α1/endostatin
expression may be regulated by Notch 3 signaling (Fig. 2 and
Supplemental Fig. 1A). Using a ligand-dependent Notch signaling
assay (Arboleda-Velasquez et al., 2011) we found that coculture of
MEFs expressing either the WT or C455R mutant NOTCH 3 withsma from mice (200 d) expressing the human Notch 3 CADASIL mutation (N3KO;
is signiﬁcantly more endostatin protein circulating in the blood of CADASIL mice.
rom Cre-inducible CADASIL (N3KO; C455Rþ/þ) or control mice (N3KO; WT76þ/þ)
þ), a Notch ligand. Monocultures had no signiﬁcant change in col18α1 mRNA ex-
ion. Expression was signiﬁcantly more robust, however, in N3KO; WT76þ/þ co-
5 (unpaired t-test).
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(Fig. 3B), though induction was signiﬁcantly less pronounced in
the MEFs expressing the C455R mutant Notch 3 receptor, com-
pared to the WT (Fig. 3B). These data are in line with the hypo-
morphic nature of the C455R allele (Arboleda-Velasquez et al.,
2011) and suggests that col18α1 expression is dependent on Notch
3 functionality.
2.2. Biomarkers in degenerating vessels
We have previously shown that expression of the R1031C CA-
DASIL mutant Notch 3 receptor triggered mural cell degeneration
in the aortas of one-year old mice (Arboleda-Velasquez et al.,
2011). To search for candidate biomarkers, we compared the pro-
teomes of aortae of R1031Cþ/; SM22-Cre mice with that of mice
expressing the human WT Notch 3 protein (WT76þ/; SM22-
Cre). Using quantitative MS (See Methods), we identiﬁed 10 pro-
teins that were more abundant and 32 proteins that were less
abundant in aortas from R1031Cþ/; SM22-Cre mice compared
to control WT76þ/; SM22-Cre mice (Supplemental Fig. 1B).
From this list, we focused on high-temperature requirement A
serine protease (HTRA1), which was upregulated by about 2-fold
in CADASIL aortas, because mutations in HTRA1 have previously
been identiﬁed as the cause of a similar SVD called cerebral au-
tosomal recessive with subcortical infarcts and leukoencephalo-
pathy (CARASIL) (Hara et al., 2009). To further support the notion
that HTRA1 is misregulated in NOTCH 3 mutant mice, we used
ELISA to measure the plasma levels of HTRA1 in the C455R model
(the model used in the antibody arrays above). ELISA analysis of
plasma from the CADASIL N3KO; C455Rþ/; SM22-Cre mice
showed a signiﬁcant increase in HTRA1, compared to N3KO;
WT76þ/; SM22-Cre controls (Fig. 4, fold-change of 1.83,
Po0.05).
2.3. Notch 3 ectodomain as a CADASIL biomarker
We investigated whether N3ECD could be detected in plasma
and whether its levels were changed in the presence of Notch
3 mutations. As a commercial ELISA is not available, we designed aFig. 4. HTRA1 protein is more abundant in the plasma of CADASIL mice. ELISA
detection of HTRA1 in the plasma of mice (200 d) expressing the human Notch
3 CADASIL mutation (N3KO; C455Rþ/; SM22-Cre), or control (N3KO; WT76þ/;
SM22-Cre) showing that there is signiﬁcantly more HTRA1 protein circulating in
the blood of CADASIL mice. Number of biological replicates is indicated in par-
enthesis. Asterisks (*) indicate P-value o0.05 (unpaired t-test).custom assay (see Methods). We detected no signal above back-
ground in WT C57BL/6 mice or in the Notch 3 knockout mice
(N3KO; WT76þ/) whereas signal was copious in mice expres-
sing the human Notch 3 protein (N3KO; WT76þ/; SM22-Cre),
indicating that our N3ECD ELISA was speciﬁc for the human
N3ECD (Data not shown and Fig. 5). The maximum linear range of
the ELISA was 2 μg/ml (Fig. 5A). This assay was also capable of
detecting N3ECD in both human plasma and serum samples, with
higher levels found in the serum (Fig. 5B, 14 ng/ul versus 51 ng/ul,
Po0.01). There was a signiﬁcant decrease in circulating N3ECD in
the plasma of CADASIL N3KO; C455Rþ/; SM22-Cre mice when
compared to N3KO; WT76þ/; SM22-Cre controls (Figs. 5C, 0.6-
fold change, Po0.01). RNA transgene expression was similar for
CADASIL and control mice (Fig. 5D).
2.4. CADASIL mice have a robust vascular smooth muscle cell loss
phenotype
Our analyses indicate that CADASIL mutations are associated
with changes in plasma levels of endostatin, HTRA1 and N3ECD in
mice. We examined the level of VSMC degeneration in the retina
of CADASIL N3KO; C455Rþ/; SM22-Cre mice. We focused on the
retina because it is part of the central nervous system, has a blood
barrier similar to that of the brain, and it has a highly stereotypic
vascular bed allowing for systematic quantiﬁcation of VSMC loss.
Using smooth muscle actin (SMA), a marker for VSMC, we ob-
served that mice carrying the C455R mutation have large gaps in
VSMC (Fig. 6). This loss appeared to occur uniformly throughout
the vasculature with about a 25% percent decrease in total cover-
age in CADASIL mice 200-days of age compared to mice carrying
the WT transgene; this is the same time point at which the bio-
marker analyses were performed, (Fig. 6E and Supplemental
Fig. 2).
Immunoﬂuorescence localization revealed strong N3ECD
staining throughout the retinal vasculature of the CADASIL mice,
N3KO; C455Rþ/; SM22-Cre, most prominently in large caliber
arteries, whereas expression in the control N3KO; WT76þ/;
SM22-Cre mice was less robust (Supplementary Fig. 3). Col18α1/
endostatin staining was also localized to retinal vessels (Supple-
mentary Fig. 4), but in contrast to the N3ECD staining was de-
tected predominantly in capillaries at the periphery of the retina
in CADASIL N3KO; C455Rþ/; SM22-Cre mice.3. Discussion
In the present work we used mouse models of CADASIL, car-
rying either the C455R or the R1031C mutations in Notch 3, to
identify increased plasma levels of col18α1/endostatin and HTRA1,
decreased levels of N3ECD, and loss of VSMC in retinal vessels as
candidate biomarkers associated with CADASIL mutations in mice.
Mice expressing the C455R mutant Notch 3 receptor displayed
robust VSMC loss in the retinal vasculature by six-months of age.
We are currently characterizing the cerebrovasculature of these
mice carrying the C455R mutation in Notch 3, however, analyses of
the retina offer signiﬁcant advantages including clear visualization
of coverage along the length of individual vessels and their bran-
ches in a tissue containing a blood barrier similar to that of the
brain. Previous analyses of the retinal vasculature in Notch 3 mu-
tant mouse models have also been helpful in identifying pericyte
loss further validating the use of the retinal vasculature as in-
formative for CADASIL phenotypes (Henshall et al., 2015; Koﬂer
et al., 2015).
Antibody arrays for angiogenesis-related proteins were used to
determine whether proteins in this category could be dysregulated
in CADASIL mice. Antibody arrays are not without limitations
Fig. 5. Detection of circulating human N3ECD using a custom ELISA. (A). Linear range of the N3ECD ELISA was found to range up to 2 μg/ml. (B) N3ECD in human plasma
and serum samples from patients with no known CADASIL mutations was signiﬁcantly more abundant in human serum than plasma. Number of biological replicates is
indicated in parenthesis. (C) ELISA detection of human N3ECD in the plasma of mice (200 d) expressing the human NOTCH 3 CADASIL mutation (N3KO; C455Rþ/; SM22-
Cre), or control (N3KO; WT76þ/; SM22-Cre) showing signiﬁcantly less N3ECD protein circulating in the blood of CADASIL mice. Number of biological replicates is indicated
in parenthesis. (D) Primary cultures of MEFs from Cre-inducible CADASIL (N3KO; C455Rþ/þ) or control mice (N3KO; WT76þ/þ), upon Adeno-Cre induction, expressed
their respective transgenes at a similar level, irrespective of monoculture or coculture conditions. Asterisks (*) indicate P-value o0.05 (unpaired t-test).
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tions within the sample mixture (Kodadek, 2001), which may
explain the discrepancy in the results for endostatin between
antibody arrays and ELISA. Notwithstanding these limitations, the
endostatin ﬁnding may be functionally relevant to the pathobiol-
ogy of CADASIL as we identiﬁed possible differences in the vas-
cular distribution of col18α1/endostatin in the retina and differ-
ences in circulating levels of endostatin have been shown to be
prognostic for ischemic stroke (Navarro-Sobrino et al., 2011). Fur-
thermore, our analyses indicated that the increased plasma levels
of col18α1/endostatin in mice carrying the C455R mutation was
not directly related to the effects of the CADASIL mutation on
Notch 3 signaling; col18α1/endostatin mRNA expression levels
were increased in cells expressing WT human Notch 3 and re-
duced in cells expressing the C455R mutant.
Using aortas from mice carrying the R1031C mutation, our MSanalysis identiﬁed HTRA1 as a misregulated protein. In humans,
CADASIL affects primarily small caliber vessels in the brain (Louvi
et al., 2006), although possible effects in large vessels have not
been systematically analyzed. In CADASIL mice, however, the
phenotype reported was overt, with aortas losing about half their
width by one year of age (Arboleda-Velasquez et al., 2011), pro-
viding a rationale for using this tissue in our study. The ﬁnding of
HTRA1 changes in affected vessels from a CADASIL mouse model is
of particular interest because mutations in this protein are asso-
ciated with a similar SVD known as CARASIL (Hara et al., 2009).
The similarities between CADASIL and CARASIL have been re-
viewed in detail (Tikka et al., 2014), however, notable similarities
include cerebral small vessel disease associated with a loss of
VSMC coverage, stroke and cognitive impairment. It is unclear how
the Notch 3 CADASIL mutations lead to HTRA1 accumulation in
vessels and in plasma and whether HTRA1 may contribute to
Fig. 6. Loss of VSMC in the retina of CADASIL mice. (A) Representative images of retinas from control mice (N3KO; WT76þ/; SM22-Cre) stained with the VSMC marker
SMA (red). (B) Same image from panel A, merged with IB4 staining (green). Overlay image shows SMA staining in 81% of the vascularized area. (C) Representative images of
retinas from CADASIL mice (N3KO; C455Rþ/; SM22-Cre) stained with the VSMC marker SMA (red). (D) Same image from panel C, merged with IB4 staining (green).
Overlay image shows SMA staining in 55% of the total vascularized area. (E) Quantiﬁcation of VSMC coverage in the CADASIL mouse model. Merged images (see Supple-
mental Fig. II) of IB4 and SMA-stained retinas from control (N3KO; WT76þ/ ; SM22-Cre) or CADASIL (N3KO; C455Rþ/; SM22-Cre) mice were quantiﬁed via Image J. To
determine VSMC coverage, positive SMA staining was normalized to IB4. The number of biological replicates is indicated in parenthesis. Asterisks (*) indicate P-value o0.05
(unpaired t-test). The scale bar is 50 mm.
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to cause a loss of function in HTRA1 activity and, by effect, a gain of
function in TGF-β signaling as the mutant HTRA1 fails to repress
TGF-β signaling (Hara et al., 2009). However, another hypothesis
postulates that CARASIL pathobiology is associated with dimin-
ished TGF-β signaling caused by defective HTRA1-mediated clea-
vage of latent TGF-β binding protein 1 (LTBP-1), a known TGF-β
facilitator protein (Beaufort et al., 2014).
The C455R CADASIL mouse model had less detectable N3ECD in
plasma when compared to controls and this difference was not
explained by differences in levels of mRNA expression. The de-
creased levels of N3ECD may be related to impaired Notch 3 sig-
naling as it is known that upon proteolytic cleavage of the Notch
receptors the Notch ectodomain is released from the receptor
expressing cell and transendocytosed into the ligand-expressing
cell (Klueg and Muskavitch, 1999), a process that may be impaired
by deﬁcient signaling. Alternatively, it is possible that mutant
N3ECD accumulates in vessels as GOMs, as it has been suggested
occurs in humans and mouse models (Monet-Lepretre et al., 2013;
Joutel et al., 2010), resulting in less detectable N3ECD in plasma of
the CADASIL mice (Fig. 5C). In support of this concept, N3ECD
staining was found to be more prominent in vessels from CADASIL
(C455R) mice compared to controls. The notion that the extra-
cellular domain of the Notch 3 receptor circulates in blood and
that its levels may change in CADASIL is novel and it remains to be
established if they are functional in this compartment. The use of
N3ECD as a plasma biomarker may have some practical ad-
vantages over the recently reported “Notch 3 score”, which re-
presents a measure for the Notch 3 accumulation based upon
immunohistochemistry analysis of postmortem brain tissue from
mice (Rutten et al., 2015), as plasma N3ECD could be measured
over time from live animals allowing prospective analyses.
Monitoring the level of these biomarkers at the beginning and
end of a trial may offer a means to quantify the efﬁcacy of a
treatment that is both inexpensive and technically feasible. Pos-
sible therapies include modulation of Notch 3 signaling to test the
Notch 3 signaling defect hypothesis in CADASIL (Arboleda-Ve-
lasquez et al., 2011). Other approaches include therapeutic Notch
3 cysteine correction in CADASIL using exon skipping or allele
speciﬁc regulation of Notch 3 expression, which will constitute adirect test of the Notch 3(ECD) toxic accumulation cascade hy-
pothesis (Rutten et al., 2016).
In conclusion, we have identiﬁed three circulating proteins in a
C445R mouse model of CADASIL: endostatin, HTRA1, and Notch 3,
which we propose as biomarkers. Changes in these proteins oc-
curred in mice by 200-days of age, coincident with a signiﬁcant
loss of VSMC in the retina. We speculate that quantiﬁcation of
these three proteins, along with analyses of VSMC coverage in the
retina, may be used as a surrogate endpoints in future preclinical
trials of CADASIL.4. Experimental procedure
4.1. Animal models
All mouse models used in this study were previously described
(Arboleda-Velasquez et al., 2008, 2011). Brieﬂy, mice express ei-
ther a wild type human NOTCH3 transgene (WT76) or a mutated
human NOTCH3 transgene (C455R or R1031C), or a Notch ligand
(DLL1); transgenes are inserted into the ROSA26 locus (Soriano,
1999) and expression occurs through Cre-mediated recombina-
tion. This study was approved by the Schepens Eye Research In-
stitute Institutional Animal Care and Use Committee (IACUC). All
procedures followed were in accordance with institutional
guidelines. Both male and female animals were included in the
study.
4.2. Plasma collection
Plasma was collected from mice with the following genotypes:
a mouse endogenous notch 3 knockout (N3KO), and a N3KO
mouse heterozygous for the WT (WT76) human or mutant
(C455R) human NOTCH3 transgene, both driven by SM22-Cre
(N3KO; WT76þ/; SM22-Cre and N3KO; C455Rþ/; SM22-Cre,
respectively). Mice were anesthetized using a mixture of ketamine
(120 mg/kg) and xylazine (20 mg/kg) using a 0.5″, 27 G needle via
intraperitoneal injection. Under anesthesia, the anterior chest wall
was removed and the left ventricle was pierced with a 0.5″, 20 G
needle. Blood was aspirated and dispensed, into a BD Vacutainer
V. Primo et al. / Brain Research 1644 (2016) 118–126124K2 EDTA, lavender top, blood collection tube (BD 367841). This
tube was inverted several times to ensure the blood made contact
with the entire surface of the EDTA-coated tube. The tube was
then placed on ice and immediately processed for plasma fol-
lowing the manufacture's protocol. Plasma was aliquoted into
100 μl volumes in Eppendorf LoBind Protein Microcentrifuge
Tubes (Eppendorf, 022431102) then stored at 80 °C until use.
4.3. Human plasma collection
Donors provided their informed consent before study entry
under guidelines approved by the institutional review board at the
University of Antioquia, Medellin, Colombia. Plasma was prepared
from blood obtained through venipuncture using BD Vacutainer
K2 EDTA tubes then stored at 80 °C until use.
4.4. Candidate biomarker screening using an angiogenesis antibody
array
Plasma (200 μl) from control mice (N3KO; WT76þ/; SM22-
Cre), CADASIL mutant mice (N3KO; C455Rþ/; SM22-Cre), and
endogenous notch 3 knockout mice (N3KO) was processed on the
Proteome Proﬁler Angiogenesis Array Kit (R&D Systems, ARY015),
according to the manufacture's protocol. For all antibody arrays,
two control and two experimental mice were used. Dot blot ana-
lysis was performed via Image J by measuring integrated density.
Background was accounted for by subtracting the integrated
density of the dot's surrounding area. A variance analysis was
conducted on each array (Figs. 1 and 2) to identify potential can-
didate proteins, as previously described (Arboleda-Velasquez et al.,
2011). Proteins of interest were considered to be differentially
abundant in plasma if the absolute value of the difference between
the two control (N3KO; WT76þ/; SM22-Cre) and two experi-
mental (N3KO; C455Rþ/; SM22-Cre) mice exceeded 1.5 times
the variation (equation below).
= ( − ) + ( − )Var Control Control Experimental Experimental1 2 1 2
2
2 2
Candidate proteins that were differentially abundant in at least
two of the three arrays were selected for validation via ELISA.
4.5. Candidate biomarker identiﬁcation utilizing a MS proteomic
screen
The material used for MS was obtained from a cohort of pre-
viously published mice and analyzed for different parameters
(Arboleda-Velasquez et al., 2011). The genotypes of the mice, all
wild type for the endogenous mouse notch 3, were heterozygous
for the WT (WT76) human or mutant (R1031C) human NOTCH3
transgene, driven by SM22-Cre (WT76þ/; SM22-Cre and
R1031Cþ/; SM22-Cre), respectively.
Aortas were isolated from one-year old mice and homogenized
in 8 M urea and 50 mmol/L Tris–HCl (pH 8). Protein from each
sample was reduced, alkylated and digested using 1 μg of Lys-C at
37 °C overnight. Peptides from proteolytic digestion were desalted
and labeled using reductive dimethylation (Boersema et al., 2008;
Hsu et al., 2003). Samples were labeled with light (CH2O-
NaBH3CN) and heavy (CD2O-NaBD3CN) reagents, respectively. The
samples were washed with 0.1% formic acid and eluted from the
column using 80% ACN and 0.5% acetic acid. Samples were then
dried down using a vacuum centrifuge. Peptides from light or
heavy aorta samples were separated by strong cation-exchange
chromatography into 20 fractions. Each fraction was dried down
by vacuum centrifugation and desalted using self-packed C18
STAGE-tips (Rappsilber et al., 2003). All liquid chromatography-tandem mass spectrometry (LC–MS/MS) data were obtained using
an LTQ-Orbitrap Discovery hybrid mass spectrometer (Thermo
Fisher, San Jose, CA). Each sample was loaded onto a reverse phase
column and separated using 95 min LC gradient of 5–27% buffer B
at a ﬂow of 0.5–1 μl/min. MS analysis was performed using a top
10 method where the MS1 scan was acquired in the Orbitrap,
followed by 10 data depended MS/MS scans on the 10 most in-
tense ions in the LTQ with CID for fragmentation. MS/MS spectra
assignments were made with the Sequest algorithm (Eng et al.,
1994) using the entire mouse IPI database (version 3.6).
Sequest searches were performed using a target-decoy strategy
(Elias and Gygi, 2010) with the mouse IPI database in correct or-
ientation (forward database) and the same database but with all
sequences in reverse orientation (reverse database). Sequest
searching was performed with a precursor ion tolerance of 50 ppm
with LysC speciﬁcity. For dimethyl labels, a static modiﬁcation of
28.0313 Da was used on the N-terminus and lysine residues. In
addition, a differential modiﬁcation of 8.044336 Da was used for
heavy proteins, respectively, on the N-terminus and lysine re-
sidues. A protein level false discovery rate of 1% was used as a
threshold for protein identiﬁcations using the target decoy strat-
egy. Quantiﬁcation of each protein was determined using the peak
heights for light and heavy forms for that protein. The criterion for
protein quantiﬁcation was a signal-to-noise ratio of 5 for at least
one of the protein species (light or heavy). Quantiﬁcation of pro-
tein level was performed by calculating the median value of the
ratios of light to heavy. Using this method of quantiﬁcation, the
contribution of single peptide protein species in the data set was
low (5%), presumably reﬂecting the high accuracy and sensitivity
of the MS methods and the high signal-to-noise cutoff used. Z
scores were given to the proteins of the R1031C mice based on the
standard deviation of the control mice. A median score of plus or
minus two was used as a cut off to generate a list of candidate
proteins (Supplemental Fig. 1B). Proteins identiﬁed as candidates
passed this cut off criteria in two independent MS experiments,
each utilizing one aorta per genotype.
4.6. Candidate validation using ELISA
Endostatin and HTRA1 were measured using commercially
available ELISA kits (MyBiosource, MBS266186 and MBS90656,
respectively), according to the provider's protocol. The genotype of
the samples tested was masked to the investigator conducting the
assays and samples were randomized in the plates to prevent
position effects. No samples were excluded from the analyses on
the basis of being outliers.
4.7. Notch 3 extracellular domain ELISA
The N3ECD sandwich enzyme-linked immunosorbent assay
was designed using commercially available antibodies. A mono-
clonal capture antibody (R&D systems MAB 1559) was coated on a
high afﬁnity binding ELISA plate (Fisher Scientiﬁc 3590) at 625 ng/
ml in 100 μl of PBS, overnight, on a rotator, at 4 °C. The plate was
then blocked using 300 μl of a 10% BSA solution in PBS at room
temperature on a rotator for 2–3 h and washed three times with
wash buffer diluted in distilled water from a 25X stock (R&D
systems WA126). Recombinant human Notch 3 extracellular do-
main region (N3ECD), which was originally used to raise the an-
tibodies (R&D systems 1559-NT-050), was used as a positive con-
trol and standard. Recombinant N3ECD serially diluted from 2 ng/
ml to 0.125 ng/ml, along with experimental serum or plasma
samples diluted 1:10 in PBS, were applied to the plate and left to
incubate on a shaker overnight at 4 °C.
Biotinylated polyclonal antibody raised against the N3ECD
(R&D Systems BAF1559) was used for detection. This antibody was
V. Primo et al. / Brain Research 1644 (2016) 118–126 125diluted in solution of PBS containing 2.5% BSA (Sigma) to a ﬁnal
concentration of 0.001 mg/ml. One hundred μl was applied to each
well and left at room temperature on a rotator for 2 h. The plate
was washed three times and a Horse Radish Peroxidase-strepta-
vidin (HRP-Strep) complex was added (R&D Systems DY998). The
HRP-Strep complex was diluted using Reagent Calibrator Diluent 2
(R&D Systems DY008) at a 1X concentration. For each well 5 μl of
HRP-Strep was added to 95 μl of the 1X calibrator diluent. One
hundred μl of the diluted HRP-Strep complex was applied to the
plate and left on a rotator at room temperature for 40 min. The
plate was then washed ﬁve times to ensure complete removal of
the HRP-Strep. After this, 100 μl of tetramethylbenzedine (TMB)
(R&D Systems DY008) was added to the plate, initiating the de-
tection phase of the reaction. Termination of this reaction took
place after 20 min using 50 μl of warm (37 °C) sulfuric acid. The
plate was then read using a SPECTRAmax plus 384 from Molecular
Devices using a 450 nm wavelength.
To test the ability of our ELISA to detect circulating N3ECD in
human samples, serially diluted plasma and serum samples, from
patients with no CADASIL mutations, were used.
4.8. Ligand-dependent Notch signaling assay
Ligand-dependent Notch signaling assay was performed as
described previously (Arboleda-Velasquez et al., 2011). Brieﬂy,
mouse embryonic ﬁbroblasts (MEFs) were isolated from N3KO;
WT76þ/þ or N3KO; C455Rþ/þ embryos for signal-receiving
cells, and from ROSA26DLL1þ /þ embryos for signal-sending cells.
Induction of the different transgenes at the ROSA26 locus was
achieved by in vitro infection with an adenovirus encoding the Cre
recombinase (adeno-Cre, 12.5 d.p.c.). This inducible transgene
system was chosen to avoid creating an early selection pressure in
the generation of the MEFs used in these experiments. MEFs were
ﬁrst generated in non-induced cells and then induction was per-
formed prior to coculture.
Signal-sending and signal-receiving cells were plated together
at a ratio of 2:1 respectively to ensure every signal-receiving cell
was exposed to the DLL1 ligand, cultured together for 48 h, before
signal-receiving cells were sorted by FACS based upon their eGFP
expression (the transgene is bicistronic including the NOTCH
3-IRES-eGFP) and directly lysed into RLT lysis buffer for RNA ex-
traction with the RNeasy kit (Qiagen). Following retro-transcrip-
tion of 600 ng total RNA (High Capacity Archive RNA-to-cDNA Kit,
Applied Biosystems), col18a1/endostatin cDNA levels were as-
sessed by TaqMan qPCR (Gene Expression Assay
Mm00487131_m1) following manufacturer's guidelines (Applied
Biosystems). Differential expression was calculated using the 2∂Ct
method with mouse Tbp (Mm00446973_m1) used to normalize
cDNA input. Relative expression was calculated by normalizing on
control samples where signal-receiving cells were cocultured with
ROSA26DLL1þ /þ cells that were not induced with Cre and therefore
did not over-express the DLL1 ligand.
4.9. Quantiﬁcation of smooth muscle cell loss in the vasculature
VSMC loss in the retinal vasculature was quantiﬁed in 10 ani-
mals: ﬁve control N3KO; WT76þ/; SM22-Cre mice and ﬁve
CADASIL N3KO; C455Rþ/; SM22-Cre mice. Animals were sacri-
ﬁced and whole eyes were removed and immediately ﬁxed over-
night in 4% paraformaldehyde at 4 °C. Following dissection and
removal of the ﬁxed retina from the eyecup, retina was washed
three times in 2 ml of phosphate buffered saline (PBS) at room
temperature for three minutes. Blocking buffer was then applied
for a minimum of 5 h at room temperature. Blocking buffer con-
sists of 1 μmol/L CaCl2, 1 μmol/L MgCl2, 1 μmol/L MnCl2, 3.9 mmol/
L sodium citrate, 1% Triton, and 0.3% goat serum, all diluted in PBS.The retinas were then incubated with 5 mg/ml of Alexa 488-
conjugated isolectin B4 glycoprotein (IB4) [1 in 200] (Invitrogen
I21411) and 10 mg/ml of Cy3-conjugated smooth muscle actin an-
tibody (SMA) [1 in 100] (Sigma C6198), in a ﬁnal volume of 300 μl
of blocking buffer overnight at 4 °C on a rotator before the retina
was then washed with PBS and then mounted for imaging. Whole
retina images were taken under 5x (x1.25) using the Zeiss Ax-
ioskope 2 mot plus microscope, using the red and green channels.
The SMA coverage was quantiﬁed using ImageJ macros as follows.
The program utilizes the signal of the IB4 positive staining to
“outline” the area of the vessels to obtain a measurement of the
total vascular area. Then the red channel is assessed for positive
signal and the area for the regions of positive signal are recorded.
The macro then produces an analyzed image, outlining the vas-
cularized area in blue and the SMA positive area in red, and a table
of results of vascular area and SMA positive area to be utilized for
calculating percent coverage from the ratio of SMA positive area to
total vascularized area.
4.10. Notch 3 and endostatin retina staining
Staining was performed in retinas of 6-month old N3KO;
C455Rþ/; SM22-Cre, and N3KO; WT76þ/;SM22-Cre mice
with antibodies against either Notch 3 extracellular domain (1 in
200) (EMD Millipore MABC594) or endostatin (1 in 120) (R&D
Systems BAF570) with Col IV, a vessel marker, [1:200] (Abcam
ab6586) in a total volume of 300 μl per retina. Retinas were pre-
pared as described above and then placed in 300 μl of blocking
solution with one of the two pairs of antibodies and imaged as
described above.
4.11. Statistical analysis
An unpaired students t-test function assuming a two tailed
distribution and equal variance as statistical comparison of the
ELISA results and VSMC loss quantiﬁcation. P values o0.05 were
considered signiﬁcant and are indicated with an asterisk (*).5. Funding
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